Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study.
CONCLUSIONS: Patient age seems to be a strong determinant in the of selection mcrpc therapy, affecting the probability of the use of chemotherapy, bone-targeted therapy, or palliative rt. Although chemotherapy is still used only in a small percentage of patients, the introduction of new therapies-such as bone-targeted therapy, docetaxel, and abiraterone-affected treatment selection over time. The availability of enzalutamide since February 2014 will likely produce additional changes in mcrpc management.
PMID: 28874892 [PubMed]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Docetaxel | Health Management | Insurance | International Medicine & Public Health | Palliative | Prostate Cancer | Radiation Therapy | Reclast | Study | Taxotere | Urology & Nephrology | Xgeva | Zometa